The European Commission (EC) has approved a marketing authorisation (MA) for Johnson & Johnson’s Tremfya (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).  It is approved in patients who had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.  Guselkumab is […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!